Sonoma Pharmaceuticals, Inc. — Director's Dealing 2016

Nov 30, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oculus Innovative Sciences, Inc. (OCLS)
CIK: 0001367083
Period of Report: 2016-11-29

Reporting Person: MCLAUGHLIN JOHN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-11-29	Common Stock, $0.0001 par value per share	A	1423	—	Acquired	7999	Direct

Footnotes

F1: The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan.